Stephen Davis - Jan 6, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Jan 6, 2024
Transactions value $
-$111,811
Form type
4
Date filed
1/9/2024, 06:00 PM
Previous filing
Oct 6, 2023
Next filing
Feb 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +9.53K +10.5% 100K Jan 6, 2024 Direct F1, F2
transaction ACAD Common Stock Sale -$112K -3.73K -3.72% $29.96 96.5K Jan 8, 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -9.53K -100% $0.00* 0 Jan 6, 2024 Common Stock 9.53K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2 Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023. On October 6, 2023, the Reporting Person filed a Form 4 which reported the same acquisition of shares in a footnote to Table I, Column 5, but inadvertently omitted such shares from the total in Table I, Column 5. The May 15, 2023 acquisition by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan is now correctly included in Table I, Column 5 of this Form 4.
F3 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The restricted stock units vest in four equal annual installments beginning January 6, 2021.